The highest achievable sales estimated by the analysts are $5,058.00M while lowest reachable sales target of $4,556.22M calculated by analysts. Analysts projected the minimum sales estimate of $4,562.00M and some analysts told that the stock may achieve maximum sales of $4,922.00M. Credit Suisse Downgraded Bristol-Myers Squibb Co on Aug 8, 2016 to ” Neutral”, Price Target of the shares are set at $63.Shares were Reiterated by Deutsche Bank on Aug 8, 2016 to “Hold” and Lowered the Price Target to $ 62 from a previous price target of $68.
Advertisement
Insider Activity: Corporate insiders look pessimistic about the outlook of the company stock that they seem to offload shares while they have -17.2 retreated so far this year. (NASDAQ:MEET) is $8.88 while analysts mean recommendation is 1.80.
Separately, TheStreet Ratings Team has a “Buy” rating with a score of B- on the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $69.91. Bristol-Myers Squibb Co makes up approx 0.10% of Homrich Berg’s portfolio.Exane Derivatives reduced its stake in BMY by selling 2,505 shares or 48.69% in the most recent quarter.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. The short ratio in the company’s stock is documented at 0.91 and the short float is around of 0.64%.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 28th.
Investors should note that on Aug 3, 2016, Bristol-Myers Squibb Co announced a cash dividend of $0.3800.
Analysts on average are expecting revenue target $4,877.65M for next quarter (Quarter Ending Dec-16). During the same period in the prior year, the firm posted $0.53 EPS. The company’s revenue was up 17.2% compared to the same quarter previous year.
BRISTOL-MYERS SQUIBB COMPANY (BMY) received consensus recommendation of “Outperform” from Analysts polled at Thomson Reuters. The company’s management has announced Oct 5, 2016 as the ex-dividend date and fixed the record date on Oct 7, 2016. On contrary, the fairly valued equity has ratio of 1 and 2. Beck Mack & Oliver LLC raised its position in shares of Bristol-Myers Squibb by 0.9% in the second quarter. Meanwhile, Director ANDREOTTI LAMBERTO sold 23,200 shares worth $1372000.74, through a transaction dated 2016-08-25. “1” rated “Sell” for the company. Following the transaction, the Director is left with a stake of 423,699 shares, now valued at $23583086. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. This transaction occurred on 2016-07-08 totals $1727000.24.
The price-earnings ratio can be seen as a means of regulating the value of per dollar of earnings through the stock market. The Hedge Fund company now holds 15,475 shares of BMY which is valued at $1,171,148. The disclosure for this sale can be found here. Castleark Management LLC now owns 748,400 shares of the biopharmaceutical company’s stock valued at $51,482,000 after buying an additional 355,090 shares during the period. Finally, Wealthfront Inc. raised its stake in Bristol-Myers Squibb by 46.1% in the fourth quarter.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Advertisement
Berenberg issued their verdict on Bristol-Myers Squibb Co (NYSE:BMY) recently.
